Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Sector Update: Health Care Stocks Edge Higher Premarket Monday
FDA Accepts Supernus Pharmaceuticals' Resubmission for Parkinson's Treatment Device, Decision Expected by February 2025
Express News | Supernus Pharmaceuticals Inc: Resubmission Is Now Considered Filed, With a User Fee Goal Date (Pdufa Date) of February 1, 2025.
Express News | Supernus Announces Spn-830 Apomorphine Infusion Device Nda Accepted for Review by FDA
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Not Quite Adding Up
Supernus Pharmaceuticals Soars on Higher 2Q Sales, Raised FY24 Guidance
Express News | Supernus Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Raised Its FY24 Revenue Guidance
Earnings Call: Supernus Pharmaceuticals Sees Robust Growth in Q2 2024
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q2 2024 Earnings Conference
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
Strong Buy Rating for Supernus Pharmaceuticals Amidst Robust Revenue Growth and Qelbree's Market Success
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
Express News | Supernus Pharmaceuticals Inc Sees FY Rev $600 - $625 Mln
Supernus Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q2 Revenue $168.3M, Vs. Street Est of $148.9M
Express News | Supernus Raises 2024 Total Revenue Guidance From $580M-$620M To $600M-$625M Vs $600.12M Est
Supernus Pharmaceuticals Q2 2024 GAAP EPS $0.36 Beats $0.05 Estimate, Sales $168.300M Beat $148.851M Estimate
Express News | Supernus Announces Second Quarter 2024 Financial Results